A Multi-center, Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Proof of Concept Study to Investigate the Efficacy and Safety of RG7314 in Individuals With Autism Spectrum Disorders (ASD)
Phase of Trial: Phase II
Latest Information Update: 06 Feb 2017
At a glance
- Drugs RG 7314 (Primary)
- Indications Pervasive child development disorders
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Roche
- 01 Feb 2017 Status changed from active, no longer recruiting to completed.
- 01 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 01 Jul 2016 Planned End Date changed from 1 Oct 2016 to 1 Sep 2016.